	US 11,674,959 B2
	Methods for identifying and preparing pharmaceutical agents for activating Tie1 and/or Tie2 receptors
Niranjan Pandey, Baltimore, MD (US); Aleksander S. Popel, Baltimore, MD (US); Jordan J. Green, Baltimore, MD (US); and Adam Mirando, Baltimore, MD (US)
Assigned to The Johns Hopkins University, Baltimore, MD (US); and AsclepiX Therapeutics, Inc., Baltimore, MD (US)
Appl. No. 16/635,862
Filed by The Johns Hopkins University, Baltimore, MD (US); and AsclepiX Therapeutics, Inc., Baltimore, MD (US)
PCT Filed Aug. 3, 2018, PCT No. PCT/US2018/045267 § 371(c)(1), (2) Date Jan. 31, 2020, PCT Pub. No. WO2019/028427, PCT Pub. Date Feb. 7, 2019.
Claims priority of provisional application 62/540,880, filed on Aug. 3, 2017.
Prior Publication US 2021/0132062 A1, May 6, 2021
Int. Cl. G01N 33/566 (2006.01); A61P 27/02 (2006.01); A61P 9/00 (2006.01); A61K 38/17 (2006.01); G01N 33/50 (2006.01); A61K 38/39 (2006.01)

CPC G01N 33/566 (2013.01) [A61K 38/1777 (2013.01); A61K 38/39 (2013.01); A61P 9/00 (2018.01); A61P 27/02 (2018.01); G01N 33/5008 (2013.01); G01N 2333/70546 (2013.01); G01N 2500/02 (2013.01)]

15 Claims

1. A method for preparing a pharmaceutical composition, comprising:

contacting a candidate α- or β-integrin-binding molecule, or a panel of candidate α- or β-integrin-binding molecules, with a integrin heterodimer, wherein the integrin heterodimer is α₅β₁and/or α_vβ₃, and quantifying heterodimer disruption by the candidate molecule; wherein quantifying heterodimer disruption comprises detecting or quantifying dissociation of the integrin heterodimer into its α integrin subunit and its β integrin subunit;

selecting an integrin-binding molecule that disrupts the integrin heterodimer; and

formulating the integrin disrupting molecule for administration to a subject, thereby preparing the pharmaceutical composition.